Skip to content

Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis

Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis - Clinical Efficacy and Safety of Oral Qing-Dai in Patients with Ulcerative Colitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000024917
Enrollment
20
Registered
2016-12-03
Start date
2016-12-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis

Interventions

Oral Qing-Dai patients from 7 to 11 : twice a day(daily dose,1g) for 12 weeks patients from 12 to 14 :twice a day(daily dose,1.5g) for 12 weeks patients 15 and over: twice a day(daily dose,2g)

Sponsors

Kumamoto red cross hospital division of gatroenterology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients from 7 to 80 Patients who had mild to moderate UC activity and were diagnosed according to the diagnostic criteria defined by the research group of inflammatory bowel disease in the Ministry of Health,Labor and Welfare in Japan.

Exclusion criteria

Exclusion criteria: colitis associated dysplasia, symptomatic intestinal stenosis a history of side effect or allergy of Chinese herbal medicine a need for potential surgery after enrollment in this study signs of other types of colitis, severe liver ,heart or renal diseases; or a history of malignant diseases, psychosomatic disorders,infectious disease. Pregnant or breastfeeding women. The patients treated with leukocyte aphaeresis,prednisolone >=40mg,adalimumab,tacrolimus or cyclosporine within 2 weeks before the commencement of the study. The patients treated with infliximab whitin 4 weeks before the commencement of the study. Changing the dose of mesalamine or prednisolone within 2 weeks before the commencement of the study. The patients treated with thiopurine within 12 weeks before the commencement of the study. Changing the dose of thiopurine within 4weeks before the commencement of the study.

Design outcomes

Primary

MeasureTime frame
Rate of clinical response at 12 weeks of treatment The clinical response is defined as a decrease in the Mayo score of 1 or more in each item.The overall safety is assessed by the patients and investigators during the visit to the clinic.

Secondary

MeasureTime frame
Rate of clinical remission and mucosal healing at 12weeks of treatment.Clinical remission is defined as a Mayo endoscopic score of 0 or 1 and other items of Mayo score of 0.Mucosal healing is defined as a Mayo endoscopic score of 0 or 1 .The serial changes in CAI score,Mayo score,partial Mayo score,Mayo endoscopic score,CRP are also assessed.

Countries

Japan

Contacts

Public ContactTuyama Atuko

Kumamoto red cross hospital division of clinical support

rinsyoukenkyu@kumamotro-med.jrc.or.jp096-384-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026